secwatch.observer — SEC 8-K summary
======================================

Issuer:     ROCKWELL MEDICAL, INC. (RMTI)
CIK:        0001041024
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0001628280-22-029592
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rockwell Medical posts record Q3 revenue of $18.7M; cuts debt to $10M; targets 2024 profitability
--------------------------------------------------------------------------------

- Q3 revenue $18.7M (+16.9% YoY), highest quarterly revenue; FY2022 guidance $65-70M.
- Cash used in ops $1.1M (down 81% QoQ); cash balance $27.6M, adjusted $22.6M after debt prepayment.
- Reduced long-term debt from $15M to $10M via $5M prepayment; 10-month interest-only period starts Dec 2022.
- Reacquired distribution rights from Baxter, adding 700+ hemodialysis customers; targets $100M annual revenue.
- Discontinued US NDAs for TRIFERIC (saves $2-3M/yr); paused FPC Home Infusion; workforce reductions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1041024/000162828022029592/0001628280-22-029592-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1041024/000162828022029592/rmti-20221114.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-029592

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer